The unaids 90-90-90 target: A clear choice for ending aids and for sustainable health and development

Journal of the International AIDS Society

Volumn 19, Issue 1, 2016, Pages

  Sidibé, Michel ^a   Loures, Luiz ^a   Samb, Badara ^a  

^a UNAIDS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADVISORY COMMITTEE; HEALTH CARE DELIVERY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LOWEST INCOME GROUP; MEN WHO HAVE SEX WITH MEN; MIGRANT; NOTE; PRIORITY JOURNAL; PROSTITUTION; TREATMENT OUTCOME; UNITED STATES;

EID: 84978835169     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.7448/IAS.19.1.21133     Document Type: Note

References (15)

1. UNAIDS. Fast-Track: ending the AIDS epidemic by 2030. Geneva: Joint United Nations Programme on HIV/AIDS; 2014.
2. Tanser F, Bärnighasen T, Grapse E, Zaidi J, Newell ML. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science. 2013;339:966-71.
3. Montaner JSG, Lima VD, Harrigan PR, Lourenço L, Yip B, Nosyk B, et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the "HIV treatment as prevention" experience in a Canadian setting. PLoS One. 2014;9:e87872.
4. Jahn A. Option B-: a stepping stone to universal access (Abstract No: 119). Presented at: Conference on Retroviruses and Opportunistic Infections; 2016 Feb. 22-25; Boston.
5. Gaolathe T, Wirth KE, Holme MP, Makhema J, Moyo S, Chakalisa U, et al. Botswana's progress towards achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey. Lancet HIV. 2016;3:e221-30. doi: http://dx.doi.org/10.1016/S2352-3018 (16) 00037-0
6. Kwarisilma D, Jain V, Owaraganise, A, et al. Virologic efficacy of ART begun at high CD4-counts via streamlined care in East Africa (Abstract No: 116). Presented at: Conference on Retroviruses and Opportunistic Infections; 2016 Feb. 22-25; Boston.
7. + United States, 2011. MMWR. 2014;64:1113-7.
8. Bradley H, Mattson C, Beer L, Huang P, Shouse RL. Increased HIV viral suppression among US adults receiving medical care, 2009-2013 (Abstract No: 53). Presented at: Conference on Retroviruses and Opportunistic Infections; 2016 Feb. 22-25; Boston.
9. Global HIV Policy Watch. International association of providers of AIDS care. [cited 2016 Mar. 25]. Available from: http://www.hivpolicywatch.org
10. UNAIDS. The gap report. Geneva: Joint United Nations Programme on HIV/AIDS; 2014.
11. UNAIDS j 2016-2021 strategy. On the fast track to end AIDS. Geneva: Joint United Nations Programme on HIV/AIDS; 2015.
12. Clinton Health Access Initiative. ARV market report: the state of the antiretroviral drug market in low- and middle-income countries, 2014-2019. Clinton Health Access Initiative; 2015.
13. Prabhu VR. New ARVs could represent over USD 3 billion in cost savings through 2025 (Abstract No: 1050). Presented at: Conference on Retroviruses and Opportunistic Infections; 2016 Feb. 22-25; Boston.
14. Correa CM. Implications of bilateral free trade agreements on access to medicines. Bull World Health Org. 2006;84:399-404.
15. Kates J, Wexler A, Lief E. Financing the response to HIV in low- and middleincome countries: international assistance from donor governments in 2014. Washington, DC: Henry J. Kaiser Family Foundation, Joint United Nations Programme on HIV/AIDS; 2015.